{"title":"FEV1/FVC 在预测慢性阻塞性肺病急性加重中的作用","authors":"","doi":"10.1016/j.rmed.2024.107780","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Whether the ratio of forced expiratory volume in 1 s to forced vital capacity (FEV<sub>1</sub>/FVC) can be used as a biomarker to predict the risk of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is unclear.</p></div><div><h3>Methods</h3><p>To investigate the predictive role of FEV<sub>1</sub>/FVC for AECOPD, we analyzed data from an observational and multicenter cohort study of 2043 patients with COPD in KOREA. Exposures were post-bronchodilator FEV<sub>1</sub>/FVC and/or percentage predicted FEV<sub>1</sub> (FEV<sub>1</sub>%pred). The outcome was the development of AECOPD during the first year of follow-up.</p></div><div><h3>Results</h3><p>During the first year of follow-up, the proportion of patients who developed AECOPD increased as FEV<sub>1</sub>/FVC decreased (<em>P</em> < 0.01). FEV<sub>1</sub>/FVC and FEV<sub>1</sub>%pred had similar predictive power for AECOPD, with optimal predictive cut-offs of approximately 0.5 for FEV<sub>1</sub>/FVC and 50 % for FEV<sub>1</sub>%pred. When the participants were classified into groups based on these cut-offs, compared with a high both-lung function group (FEV<sub>1</sub>/FVC≥0.5 and FEV<sub>1</sub>%pred≥50 %), the low-FEV<sub>1</sub> group (FEV<sub>1</sub>/FVC≥0.5 and FEV<sub>1</sub>%pred<50) had a modestly increased risk of severe AECOPD (adjusted odds ratio[aOR] = 3.12; 95 % confidence interval[CI] = 1.59–6.16), while the risk of severe AECOPD was the highest in the low both-lung function group (FEV<sub>1</sub>%pred<50 % and FEV<sub>1</sub>/FVC<0.5) (aOR = 5.16; 95 % CI = 3.34–7.97).</p></div><div><h3>Conclusions</h3><p>FEV<sub>1</sub>/FVC is a spirometric biomarker predictive of AECOPD. In countries where FEV<sub>1</sub>%pred is not available for their population, FEV<sub>1</sub>/FVC could be used as a biomarker for assessing the risk of AECOPD. In countries where accurate FEV<sub>1</sub>%pred is available, both FEV<sub>1</sub>%pred and FEV<sub>1</sub>/FVC could be used to provide additional information to assess the risk of AECOPD.</p></div><div><h3>Key message</h3><p>This study showed that FEV<sub>1</sub>/FVC had similar predictive power for AECOPD compared with percentage predicted FEV<sub>1</sub>. Furthermore, the use of both FEV<sub>1</sub> and FEV<sub>1</sub>/FVC provides additional information for the risk assessment of AECOPD.</p></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The role of FEV1/FVC in the prediction of acute exacerbation of COPD\",\"authors\":\"\",\"doi\":\"10.1016/j.rmed.2024.107780\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Whether the ratio of forced expiratory volume in 1 s to forced vital capacity (FEV<sub>1</sub>/FVC) can be used as a biomarker to predict the risk of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is unclear.</p></div><div><h3>Methods</h3><p>To investigate the predictive role of FEV<sub>1</sub>/FVC for AECOPD, we analyzed data from an observational and multicenter cohort study of 2043 patients with COPD in KOREA. Exposures were post-bronchodilator FEV<sub>1</sub>/FVC and/or percentage predicted FEV<sub>1</sub> (FEV<sub>1</sub>%pred). The outcome was the development of AECOPD during the first year of follow-up.</p></div><div><h3>Results</h3><p>During the first year of follow-up, the proportion of patients who developed AECOPD increased as FEV<sub>1</sub>/FVC decreased (<em>P</em> < 0.01). FEV<sub>1</sub>/FVC and FEV<sub>1</sub>%pred had similar predictive power for AECOPD, with optimal predictive cut-offs of approximately 0.5 for FEV<sub>1</sub>/FVC and 50 % for FEV<sub>1</sub>%pred. When the participants were classified into groups based on these cut-offs, compared with a high both-lung function group (FEV<sub>1</sub>/FVC≥0.5 and FEV<sub>1</sub>%pred≥50 %), the low-FEV<sub>1</sub> group (FEV<sub>1</sub>/FVC≥0.5 and FEV<sub>1</sub>%pred<50) had a modestly increased risk of severe AECOPD (adjusted odds ratio[aOR] = 3.12; 95 % confidence interval[CI] = 1.59–6.16), while the risk of severe AECOPD was the highest in the low both-lung function group (FEV<sub>1</sub>%pred<50 % and FEV<sub>1</sub>/FVC<0.5) (aOR = 5.16; 95 % CI = 3.34–7.97).</p></div><div><h3>Conclusions</h3><p>FEV<sub>1</sub>/FVC is a spirometric biomarker predictive of AECOPD. In countries where FEV<sub>1</sub>%pred is not available for their population, FEV<sub>1</sub>/FVC could be used as a biomarker for assessing the risk of AECOPD. In countries where accurate FEV<sub>1</sub>%pred is available, both FEV<sub>1</sub>%pred and FEV<sub>1</sub>/FVC could be used to provide additional information to assess the risk of AECOPD.</p></div><div><h3>Key message</h3><p>This study showed that FEV<sub>1</sub>/FVC had similar predictive power for AECOPD compared with percentage predicted FEV<sub>1</sub>. Furthermore, the use of both FEV<sub>1</sub> and FEV<sub>1</sub>/FVC provides additional information for the risk assessment of AECOPD.</p></div>\",\"PeriodicalId\":21057,\"journal\":{\"name\":\"Respiratory medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0954611124002555\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0954611124002555","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
The role of FEV1/FVC in the prediction of acute exacerbation of COPD
Background
Whether the ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC) can be used as a biomarker to predict the risk of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is unclear.
Methods
To investigate the predictive role of FEV1/FVC for AECOPD, we analyzed data from an observational and multicenter cohort study of 2043 patients with COPD in KOREA. Exposures were post-bronchodilator FEV1/FVC and/or percentage predicted FEV1 (FEV1%pred). The outcome was the development of AECOPD during the first year of follow-up.
Results
During the first year of follow-up, the proportion of patients who developed AECOPD increased as FEV1/FVC decreased (P < 0.01). FEV1/FVC and FEV1%pred had similar predictive power for AECOPD, with optimal predictive cut-offs of approximately 0.5 for FEV1/FVC and 50 % for FEV1%pred. When the participants were classified into groups based on these cut-offs, compared with a high both-lung function group (FEV1/FVC≥0.5 and FEV1%pred≥50 %), the low-FEV1 group (FEV1/FVC≥0.5 and FEV1%pred<50) had a modestly increased risk of severe AECOPD (adjusted odds ratio[aOR] = 3.12; 95 % confidence interval[CI] = 1.59–6.16), while the risk of severe AECOPD was the highest in the low both-lung function group (FEV1%pred<50 % and FEV1/FVC<0.5) (aOR = 5.16; 95 % CI = 3.34–7.97).
Conclusions
FEV1/FVC is a spirometric biomarker predictive of AECOPD. In countries where FEV1%pred is not available for their population, FEV1/FVC could be used as a biomarker for assessing the risk of AECOPD. In countries where accurate FEV1%pred is available, both FEV1%pred and FEV1/FVC could be used to provide additional information to assess the risk of AECOPD.
Key message
This study showed that FEV1/FVC had similar predictive power for AECOPD compared with percentage predicted FEV1. Furthermore, the use of both FEV1 and FEV1/FVC provides additional information for the risk assessment of AECOPD.
期刊介绍:
Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants.
Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.